Genelux Corporation

GNLX Healthcare Biotechnology

Genelux Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8,000.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, EPS fell 5.00% and free cash flow fell 11.2%, each against the same quarter a year earlier.

2.42 0.06 −2.42%
Market cap
$112.2M
P/E
0.0×
Fwd P/E
−3.6×
Dividend yield
—
F-score
3/9
Altman Z
−13.06
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
4.20 2.43 3.68 2.39
Net Debt/EBITDA
2.56 1.55 2.84 1.93
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.19) (0.18) (0.16) (0.18)
Book value per Share
0.49 0.31 0.52 0.36
Free Cash Flow
(7.09) (6.63) (6.98) (7.98)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates